Introduction
In the daily practice of anaesthesia, patients who are infected with the human immunodeficiency virus (HIV) will present. These patients can be at various stages of the disease process, and may or may not be on antiretroviral therapy (ART). This article will concentrate mainly on the clinical and practical aspects of dealing with a patient with HIV for anaesthetists.
Clinical manifestations
Patients who are infected with HIV may present at any stage of the disease process, and each stage is characterised by the presence of certain clinical stigmata. The World Health Organization (WHO) has developed a clinical staging system ranging from Stage 1 (essentially asymptomatic) to Stage 4 [acquired immune deficiency syndrome (AIDS)-defining].
By taking a history, examining the patient, and carrying out special investigations, the stage of the disease process in the patient can be determined.
The following symptoms and signs should be sought during the taking of the history and the examination: 
Special investigations
The choice of special investigations should be guided by the history and examination.
Blood tests
Blood tests should include:
• A full blood count: anaemia, thrombocytopaenia, increased or decreased white cell count • Urea and electrolyte: a low total CO 2 may indicate the presence of a lactic acidosis, in which case, carrying out an arterial blood gas should be considered • Clotting profile: hypercoagulability • Liver function tests: hypoalbuminaemia, and raised liver enzymes, especially with nevirapine • Arterial blood gas analysis: hyperlactataemia and lactic acidosis • Viral load and CD4+ count: mortality is inversely related to CD4+ count Chest X-ray • Cardiac shadow abnormalities (pericardial effusion), and dilated cardiomyopathy • Evidence of infection, such as bacterial pneumonia, Pneumocystis jiroveci pneumonia (PCP), tuberculosis • Kaposi's sarcoma of airway or mediastinum • Mediastinal compression or lymphadenopathy.
Electrocardiogram

• Conduction defects • Prolonged QT time
Antiretroviral drugs
Patients who are HIV positive may be on ART. These drugs can have significant side-effects, and can also interact with anaesthetic agents.
Treatment of patients (who are HIV positive) with antiretroviral drugs, is based on guidelines provided by the National Department of Health.
Antiretroviral drugs (Table I) 
Who is eligible to receive antiretroviral treatment?
The Standardized National Eligibility Criteria for starting ART regimens in adults and adolescents are as follows: What are the antiretroviral treatment regimen in South Africa? 
Antiretroviral treatment drug side-effects Reverse transcriptase inhibitors: NRTIs and NtRTIs
• NRTIs are associated with many adverse effects, most of which are benign and self-limiting.
• Mainly renal elimination.
• Mitochondrial toxicity may result in pancreatitis, hepatosteatosis, peripheral neuropathy, and lactic acidosis.
• Abnormal fat deposition can result in central obesity and facial fat wasting, as well as deranged lipid distribution, leading to metabolic derangement.
• Zidovudine is associated with a high incidence of 
NNRTIs
• Rashes, including Steven-Johnson syndrome, and toxic epidermal necrolysis.
• Nevirapine is used in the prevention of mother-to-child transmission. It is also a potent inducer of cytochrome p450 enzymes. As a result, it induces its own metabolism, and may lead to a reduction in the effect of midazolam, rifampicin and oral contraceptives.
• Markedly increase opioid metabolism requires an increased dose of synthetic opioids. • Premature atherosclerosis, metabolic syndrome with glucose intolerance, decreased high-density lipoprotein levels and hypercholesterolaemia also occur.
• NNRTIs have a very long half-life, resulting in a "hangover effect" on discontinuation, i.e. increased risk of resistance to ARV.
PIs
• All are associated with metabolic abnormalities, including dyslipidaemia, insulin resistance with hyperglycaemia, and lipodystrophy ("protease paunch").
• Cause gastrointestinal tract disturbances and abnormal liver functions.
• Impair Vitamin D metabolism, leading to osteoporosis.
• The effects of midazolam and diazepam are potentiated, and require dose reduction. Lorazepam is probably safer. • Significant reduction in metabolism of alfentanil and fentanyl is described. Reduction in clearance of fentanyl by nearly 70% has been described with ritonavir. Remifentanyl and morphine are safe alternatives. Pethidine is not recommended because of the risk of metabolite accumulation and seizures.
• Sodium thiopentone and dexamethasone may reduce PI concentration.
• Simvastatin and lovastatin are absolutely contraindicated, as there is a high risk of rhabdomyolysis and myopathies. Pravastatin is safe.
• PIs increase the cardiac toxicity of amiodarone, quinidine and disopyramide. May potentiate digoxin toxicity.
• Disulfiram-like reaction with metronidazole.
Fusion inhibitors
• Expensive • Risk of hypersensitivity • Neutropaenia.
CCRAs
• Elevations in liver function tests, coughing, diarrhoea and nausea. 
Patient group Treatment Comments
Failing on a stavudine-or zidovudine-based first-line regimen
Tenofovir + lamivudine/emtracitabine + lopinavir/ritonavir Virological failure must be followed by intensive adherence management as resuppression is often possible. If repeat viral load remains >1 000 in 3 months despite adherence intervention, switch.
Failing on a tenofovir-based first-line regimen Zidovudine + lamivudine + lopinavir/ritonavir Virological failure must be followed by intensive adherence management as resuppression is often possible. If repeat viral load remains > 1 000 in 3 months despite adherence intervention, switch. 
Failing any second-line regimen Specialist referral Virological failure on protease inhibitors is almost always due to non-adherence. Intensively exploring and addressing issues relating to causes of non-adherence will most often lead to resuppression. If viral load remains high, refer where possible, but maintain on failing regimen.
Integrase inhibitors
• Elevations in amylase and liver function tests, pruritus and rashes, headaches.
Lactic acidosis
Lactic acidaemia can occur in patients taking NRTIs. The lactate is elevated in the presence of a normal pH, and is not of clinical importance, provided the patient is asymptomatic.
However, lactic acidosis is a rare, but potentially fatal complication of ART. It carries a mortality of up to 77%. The symptoms may be vague and non-specific, such as nausea, vomiting, abdominal pain, fatigue and weight loss. The patient may also present with hepatic steatosis and dysfunction. Treatment involves stopping the NRTI, and instituting supportive care. Patients booked for elective surgical procedures who have lactic acidosis should be postponed until the lactic acidosis has resolved.
Immune reconstitution inflammatory syndrome
Immune reconstitution inflammatory syndrome (IRIS) occurs when improving immune function unmasks a previously occult opportunistic infection which subsequently presents with an unusually aggressive inflammatory presentation. Patients with advanced HIV may become ill with IRIS. usually during the first three months of ART. Tuberculosis is the most common presenting IRIS reaction in South Africa. About a third of patients starting ART when on treatment for tuberculosis, will experience recurrence of their tuberculosis signs and symptoms, or new manifestations. Rashes, including zoster, herpes, molluscum and others, cryptococcal meningitis, and hepatitis due to hepatitis B or C, are other manifestations of IRIS.
IRIS is not indicative of drug failure or side-effects, and is not a reason to stop ART.
Perioperative fasting
Patients should continue treatment protocol despite nil per os orders, as there is clear evidence of increased mortality and adverse events during temporary interruption of the ART regimen. ARVs may also be administered via gastric or jejunal feeding tubes.
Premedication
Beware of potential drug interactions with midazolam and diazepam. Lorazepam and oxazepam are safer.
Universal precautions
Universal precautions are essential, including gloving and eye-splash protection. Avoid unnecessary invasive procedures, and dispose of sharps safely.
Potentially infectious materials include blood and bloodstained fluids or materials, vaginal or penile secretions, and tissue fluids, including ascites, liquor, cerebrospinal fluid, pleural and pericardial fluid, and breast milk.
Sweat, tears, saliva, sputum, urine and stools, are generally considered to be non-infectious, unless contaminated by the above.
The risk of HIV infection from needle-stick injury is 0.3%, and the risk of HIV transmission from exposure to mucous membranes is 0.1%, and to non-intact skin, < 0.1%.
The highest risk of infection is injury from hollow-bore needles containing visible blood, large-volume exposure, a deep injury, and if the patient has a high viral load.
Intraoperative management General anaesthesia
General anaesthesia results in immunosuppression within 15 minutes of induction, and lasts for up to 11 days postoperatively. The possibility of unpredictable drug interactions must always be considered.
Etomidate is possibly the safest for induction (no metabolism by cytochrome P450). However, the risk of adrenal insufficiency should be considered. There are no clear contraindications to propofol or sodium thiopentone.
Desflurane is theoretically advantageous due to minimal metabolism.
Remifentanil is the opioid of choice. Morphine is generally safe. Doses must be tailored according to response, and may need to be increased in patients on NNRTIs, or reduced in patients using PIs. In general, pethidine should be avoided.
Scoline is probably safe. However, the risk of hyperkalaemia in patients with myopathy and neuropathy can exist.
Atracurium and cis-atracurium with organ-independent metabolism are theoretically safest.
Neuraxial and regional anaesthesia
